



Back to School program

Helping staff and students benefit
from in-person learning during COVID-19

Knowing what comes next

Quest Diagnostics understands that the COVID-19 pandemic has had a significant impact on schools across America, and that resulting school closures have profoundly impacted the short- and long-term social, emotional, and behavioral health of children of all ages. While administrators, teachers, staff, and parents may be understandably concerned about COVID-19 exposure, key mitigation strategies—including testing—can help moderate the risk of COVID-19 in schools.¹

Reliable, accurate testing when it matters most: SARS-CoV-2 (COVID-19) testing options

Our **Back to School program** testing solutions are designed to help school districts easily monitor their COVID-19 status. Armed with this information, districts can quickly implement additional mitigation strategies, including quarantining, contact tracing, and other methods designed to help minimize the spread of infection.

- **SARS-CoV-2 (COVID-19) molecular test** aids in the detection of an active SARS-CoV-2 (COVID-19) infection
- **SARS-CoV-2 (COVID-19) immunoglobulin (IgG) antibody test** can help identify recent or prior infection with SARS-CoV-2

Our Back to School solution can help you:



Understand your
risk of exposure



Develop and operationalize
testing strategies



Help enable
in-person learning



Capture, analyze, and
maintain testing data

“**Testing to diagnose COVID-19 is part of a comprehensive strategy** and should be used in conjunction with promoting behaviors that reduce spread, maintaining healthy environments, maintaining healthy operations, and preparing for when someone gets sick. Schools that have opened for any in-person classes (including hybrid, which includes a combination of in-person and virtual classes) can benefit from developing a testing strategy.¹”

— Centers for Disease Control and Prevention (CDC)

A 3-pronged strategy to help keep your students and staff in the classroom

While every district's approach will vary based on the unique circumstances of the local community, we've developed a baseline approach based on the Centers for Disease Control and Prevention (CDC) interim considerations for testing in school settings.^{1,b}

1

Testing people with symptoms

- Advise teachers, staff, and students to stay home if they are sick or have been exposed to COVID-19
- If a teacher, staff, or student becomes sick at school, connect with a healthcare provider for evaluation and to determine next steps
- If testing is recommended, test teachers, staff, and students with a SARS-CoV-2 (COVID-19) molecular^c test performed at a physician's office or local collection site

2

People without symptoms who are close contacts of positive COVID-19 cases

- Teachers, staff, or students should stay home and monitor for symptoms as appropriate
- Aggressively contact trace to limit the potential spread

3

Testing persons in an outbreak setting

- In conjunction with the local health department, facilitate contact tracing and testing for schools with an active outbreak
- If appropriate, SARS-CoV-2 (COVID-19) molecular tests can be performed at a physician's office or local collection site

^bSchool-based testing should never be conducted without consent from a parent or legal guardian (for minor students) or from the individual him or herself (for adults). Assent may also be considered for minor students.¹

Nationwide network of SARS-CoV-2 testing access

Active infection testing

Quest Diagnostics is working with Walmart® Neighborhood Markets to provide convenient pharmacy drive-thru SARS-CoV-2 (COVID-19) molecular testing for any patient who meets the guidelines outlined by the CDC.



Antibody testing

Across the US, our 2,250 Quest Diagnostics Patient Service Centers are open and offering SARS-CoV-2 (COVID-19) IgG antibody testing^c for all patients.

^cSpecimen collection for molecular testing for active SARS-CoV-2 (COVID-19) infection is not available at Quest Diagnostics Patient Service Centers. Do not send patients suspected of active SARS-CoV-2 (COVID-19) infection to our centers.



To learn more about our Back to School program, visit [QuestBackToSchool.com](https://www.questdiagnostics.com/backtoschool)

The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

- The antibody tests and the molecular tests (together "All tests") have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner

Reference

1. Coronavirus Interim considerations for testing for K-12 school administrators and public health officials. Centers for Disease Control and Prevention (CDC). Updated October 13, 2020. Accessed October 16, 2020. <https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-testing.html>

Image content features a model and is intended for illustrative purposes only.

[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2020 Quest Diagnostics Incorporated. All rights reserved. MI9827 11/2020

